GERALD M. PERLOW, M.D.; BIMAL P. JAIN, M.D.; STEPHEN G. PAUKER, M.D.; HARVEY S. ZARREN, M.D.; DANIEL C. WISTRAN, M.D.; RALPH L. EPSTEIN, M.D.
PERLOW GM, JAIN BP, PAUKER SG, ZARREN HS, WISTRAN DC, EPSTEIN RL. Tocainide-Associated Interstitial Pneumonitis. Ann Intern Med. 1981;94:489-490. doi: 10.7326/0003-4819-94-4-489
Download citation file:
Published: Ann Intern Med. 1981;94(4_Part_1):489-490.
Tocainide, an investigational antiarrhythmic drug with chemical and pharmacologic properties similar to those of lidocaine, is effective when administered orally in treating ventricular arrhythmias (1-4). At present tocainide is not in clinical use in the United States or Europe, but its efficacy strongly suggests that it will soon be introduced for clinical use. Typical doses are between 400 and 800 mg every 8 hours. The commonest side effects have been anorexia, nausea, lightheadedness, tremors, sweating, hot flashes, anxiety, paresthesia, vomiting, abdominal pain, and altered vision and hearing. No pulmonary complications appear to have been reported. A single reported incident of
Learn more about subscription options.
Register Now for a free account.
Cardiology, Infectious Disease, Pneumonia, Pulmonary/Critical Care, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only